EUVIMEDEUVIMED entdecken
Crossref

Prognostic value of the “dynamic” R2‐ISS in patients with multiple myeloma undergoing anti‐CD38 antibody‐based triplet therapies

Taku Kikuchi iD, Yuki Oda, Ukyo Kondo, Nobuhiro Tsukada, Kodai Kunisada, Chiaki Matsumoto, Moe Nomura-Yogo, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki und 2 weitere

Hematological Oncology · 2024

DOI: 10.1002/hon.3302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2024. Verfasst von Taku Kikuchi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma, ADP-ribosyl Cyclase 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To retrospectively analyze whether the second revision of the international staging system (R2‐ISS) influenced prognosis at treatment initiation in patients with multiple myeloma (MM) receiving anti‐CD38 antibody‐based triplet treatments. High‐risk chromosomal abnormalities were examined from diagnosis to treatment initiation and considered positive if detected once. R2‐ISS was recalculated at the initiation of treatment and defined as “dynamic R2‐ISS." Data from 150 patients who underwent the defined treatments were analyzed. The median progression‐free survival (PFS) was 19.5 months, and the median overall survival (OS) was 36.5 months. Dynamic R2‐ISS significantly stratified prognoses for both PFS and OS. The median PFS for patients with dynamic R2‐ISS IV was 3.3 months, and the median OS was 11.7 months, indicating extremely poor outcomes. Although the Revised International Staging System (R‐ISS) calculated at the initiation of treatment significantly stratified treatment outcomes, the patients classified as R‐ISS could be further stratified by R2‐ISS to provide better prognostic information. Dynamic R2‐ISS showed potential as a prognostic tool in patients with MM who are treated with anti‐CD38 antibody‐based triplet therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaADP-ribosyl Cyclase 1HumansMaleFemaleMiddle AgedAgedPrognosisRetrospective StudiesAdultAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsNeoplasm StagingSurvival RateMembrane Glycoproteins

Stichwörter der Autor:innen

R2‐ISSanti‐CD38 antibodydynamic risk predictionmultiple myeloma

Substanzen

ADP-ribosyl Cyclase 1CD38 protein, humanMembrane Glycoproteins

Autor:innen und Institutionen

  • Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
  • Department of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan.

ORCID-Profile: Taku Kikuchi

Zitieren

APA

Kikuchi, T., Oda, Y., Kondo, U., Tsukada, N., Kunisada, K., Matsumoto, C., Nomura-Yogo, M., Sato, K., Takei, T., Ogura, M., Abe, Y., Suzuki, K., Hosoya, O., & Ishida, T. (2024). Prognostic value of the “dynamic” R2‐ISS in patients with multiple myeloma undergoing anti‐CD38 antibody‐based triplet therapies. Hematological Oncology. https://doi.org/10.1002/hon.3302

Vancouver

Kikuchi T, Oda Y, Kondo U, Tsukada N, Kunisada K, Matsumoto C, et al. Prognostic value of the “dynamic” R2‐ISS in patients with multiple myeloma undergoing anti‐CD38 antibody‐based triplet therapies. Hematological Oncology. 2024. doi:10.1002/hon.3302

BibTeX
@article{Kikuchi2024,
  author = {Kikuchi, Taku and Oda, Yuki and Kondo, Ukyo and Tsukada, Nobuhiro and Kunisada, Kodai and Matsumoto, Chiaki and Nomura-Yogo, Moe and Sato, Kota and Takei, Tomomi and Ogura, Mizuki and Abe, Yu and Suzuki, Kenshi and Hosoya, Osamu and Ishida, Tadao},
  title = {Prognostic value of the “dynamic” R2‐ISS in patients with multiple myeloma undergoing anti‐CD38 antibody‐based triplet therapies},
  journal = {Hematological Oncology},
  year = {2024},
  doi = {10.1002/hon.3302}
}
Kostenlos starten →